Coherus Oncology, Inc. (CHRS) scores 42 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $484.83, representing a 28253% margin of safety. Quantitative score: 60/100. Qualitative score: 20/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.